CompletedPhase 2ACTRN12607000267459

A Phase 1/2, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Topical Antimicrobial (NEO101) in the Reduction or Eradication of Staphylococcus aureus Nasal Carriage among Adults

Sponsor

Neosil, Inc.

Enrollment

36 participants

Start Date

Jun 8, 2007

Study Type

Interventional

Conditions

Stable nasal carriage of Staphylococcus aureus in adults

Summary

This study will evaluate the safety of a new antimicrobial (NEO101) applied to the inside of the nose twice-daily for 7 days. The reduction or eradication by the antimicrobial of nasal Staphylcoccus aureus will also be evaluated.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This Phase 1/2 study tests a new topical antimicrobial treatment for people who carry Staphylococcus aureus bacteria in their nose. It is for adults aged 18 to 65 in good general health whose nasal cultures test positive for S. aureus. Participants apply the treatment or placebo inside their nose and are monitored for safety, tolerability, and whether the bacteria is eliminated.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Eligible subjects will receive either 0.95% NEO101, which will be administered twice daily by topical application to the inside of each nostril, for a 7-day treatment course. A 14-day safety and effi

Eligible subjects will receive either 0.95% NEO101, which will be administered twice daily by topical application to the inside of each nostril, for a 7-day treatment course. A 14-day safety and efficacy assessment period will follow the treatment period.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000267459